| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.8 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.039 | 0.8 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |